argenx NV ADR (ARGX)vsBridgeBio Pharma Inc (BBIO)
ARGX
argenx NV ADR
$984.39
+0.04%
HEALTHCARE · Cap: $64.63B
BBIO
BridgeBio Pharma Inc
$72.44
-0.08%
HEALTHCARE · Cap: $14.62B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 645% more annual revenue ($5.32B vs $713.07M). ARGX leads profitability with a 32.3% profit margin vs -97.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
BBIO
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$2371.09
Current Price
$984.39
$1386.70 discount
Margin of Safety
+88.0%
Fair Value
$636.90
Current Price
$72.44
$564.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Revenue surging 120.4% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 183.0x book value
0.0% earnings growth
Weak financial health signals
ROE of -1790.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : BBIO
The strongest argument for BBIO centers on Revenue Growth, Debt/Equity. Revenue growth of 120.4% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : BBIO
The primary concerns for BBIO are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while BBIO is a hypergrowth play — different risk/reward profiles.
BBIO carries more volatility with a beta of 0.97 — expect wider price swings.
BBIO is growing revenue faster at 120.4% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 31/100), backed by strong 32.3% margins and 59.3% revenue growth. BBIO offers better value entry with a 88.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
BridgeBio Pharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?